Roivant Sciences Sees Unusually High Options Volume (NASDAQ:ROIV)

Roivant Sciences Ltd. (NASDAQ:ROIV) was the target of unusually large options trading on Tuesday. Traders acquired 7,491 call options on the company. This is an increase of 421% compared to the average volume of 1,438 call options.

Insiders Place Their Bets

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of the firm’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $35.77, for a total transaction of $7,154,000.00. Following the completion of the sale, the chief executive officer owned 1,599,154 shares of the company’s stock, valued at $57,201,738.58. This trade represents a 11.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Daniel Gold sold 12,380 shares of Roivant Sciences stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $35.28, for a total transaction of $436,766.40. Following the transaction, the director directly owned 13,689,166 shares of the company’s stock, valued at approximately $482,953,776.48. This trade represents a 0.09% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,055,913 shares of company stock worth $107,261,258 in the last quarter. Insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ROIV. SBI Securities Co. Ltd. increased its position in Roivant Sciences by 1,740.3% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after purchasing an additional 1,166 shares in the last quarter. Allworth Financial LP boosted its position in Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after buying an additional 583 shares in the last quarter. Kestra Advisory Services LLC bought a new stake in shares of Roivant Sciences during the fourth quarter worth $47,000. Parallel Advisors LLC grew its stake in shares of Roivant Sciences by 33.7% during the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after buying an additional 520 shares during the last quarter. Finally, CIBC Private Wealth Group LLC increased its holdings in shares of Roivant Sciences by 7,614.3% during the fourth quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock worth $59,000 after buying an additional 2,665 shares in the last quarter. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Trading Up 19.4%

NASDAQ ROIV traded up $6.76 on Tuesday, hitting $41.69. 11,196,290 shares of the company’s stock were exchanged, compared to its average volume of 6,163,936. The stock has a 50-day moving average of $35.30 and a 200-day moving average of $31.26. The stock has a market cap of $30.11 billion, a price-to-earnings ratio of -79.15 and a beta of 1.12. Roivant Sciences has a 52 week low of $12.90 and a 52 week high of $42.09.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. The company had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $2.06 million. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. As a group, analysts predict that Roivant Sciences will post -2 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have weighed in on ROIV. Piper Sandler reiterated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. Jefferies Financial Group increased their target price on Roivant Sciences from $42.00 to $52.00 and gave the stock a “buy” rating in a report on Tuesday. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a research report on Tuesday, August 25th. Guggenheim boosted their price target on Roivant Sciences from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Finally, Citigroup upped their price objective on shares of Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Roivant Sciences presently has an average rating of “Moderate Buy” and an average price target of $37.14.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.